Tumor-specific Th17-polarized cells eradicate large established melanoma.

By P. Muranski, Andrea Boni, P. Antony, L. Cassard, K. Irvine, A. Kaiser, C. Paulos, D. Palmer, C. Touloukian, Krzysztof Ptak and 7 more. Blood, 2008

860 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/3c133937f1d096e4092a1a31b1799f63442869a8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. James P. Allison
2. S. Rosenberg
3. N. Restifo
4. J. Wolchok
5. M. Dudley
6. C. June
7. D. Pardoll
8. Yeonseok Chung

Citations in the corpus

• Adoptive immunotherapy for cancer: harnessing the T cell response (2012, background): “Th17 hücreleri etkili tümör reddini oluşturma kapasitesine sahiptirler (141,142), ama sadece Th1 benzeri özelliklerle birlikte efektör T hücrelerine farklılaşma kapasiteleri varsa (143).”
• The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “ICOS costimulation drives human T cells to a Th17 cell phenotype (Paulos et al., 2010), and in certain models, Th17 cells are preferable for adoptive transfer (Muranski et al., 2008).”
• IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway (2009, background): “, 2008), it remains controversial whether IL-17 promotes or inhibits cancer progression (Numasaki et al., 2003; Numasaki et al., 2005; Muranski et al., 2008; Nam et al., 2008; Kryczek et al., 2009; Xiao et al., 2009; Zhang et al., 2009).”
• Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma (2013, methodology): “Previously described BW RAG/ Trp1 transgenic mice (Muranski et al., 2008) were provided by N. Restifo (National Cancer Institute, Bethesda, MD) and crossed to B6.”
• Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts (2010, methodology): “Although previous studies have indicated that Th17 cells polarized in vitro are capable of inducing tumor rejection (Muranski et al., 2008), we did not observe differentiation of CD4+Trp1+ cells into IL-17 producers in vivo (unpublished data).”
• Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy (2014, background): “Bioluminescent imaging was used to measure the distribution and expansion kinetics of the adoptively transferred Trp1 cells.”
• Th17 cells promote cytotoxic T cell activation in tumor immunity (2009, methodology): “However, the effect of Th17 cell vaccination was dependent on IFN-g and independent of IL-17 and IL-23 (Muranski et al., 2008).”